Radiopharm Theranostics (RAD.AX) Surges 25 % in 24‑Hour Trading Session
Radiopharm Theranostics Limited (RAD.AX) experienced a notable 25 % rally during the 24‑hour period concluding at 08:27 AM Central Europe on Wednesday, 21 March 2026. At the close, a single share was available for approximately AUD 0.01 on major exchanges, a steep rise from its recent trading range.
Trading Metrics
| Metric | Value |
|---|---|
| Current price | AUD 0.01 |
| Volume (last 24 h) | AUD 11.1 k |
| Total shares outstanding | 1.7 bn |
| Market capitalisation | AUD 17.4 mn |
| 200‑day simple moving average | AUD 0.02 |
| 52‑week high | AUD 0.04 (16 Dec 2025) |
| 52‑week low | AUD 0.00 (16 Oct 2026) |
| Month‑end change | –28.57 % |
The recent surge marks a significant correction from the month‑end decline, suggesting short‑term volatility may be giving way to a more sustained upward trajectory. The 200‑day moving average at AUD 0.02 now lies comfortably above the current price, providing a potential support level as the stock consolidates.
Comparative Context
The broader resource‑driven sector remained mixed over the same period:
- Venus Metals (VMC.AX) – down 6.06 % to AUD 0.09 (market cap AUD 20.5 mn)
- Mammoth Minerals (M79.AX) – down 3.95 % to AUD 0.04 (market cap AUD 20.4 mn)
- Gratifii (GTI.AX) – flat at AUD 0.03 (market cap AUD 20.7 mn)
- Strategic Elements (SOR.AX) – up 2.70 % to AUD 0.04 (market cap AUD 20.7 mn)
- Ozaurum (OZM.AX) – down 4.29 % to AUD 0.06 (market cap AUD 20.3 mn)
Against this backdrop, Radiopharm Theranostics’ rally stands out, underscoring investor confidence in its biotech focus amid a volatile sector landscape.
Strategic Outlook
Radiopharm Theranostics Limited is positioned at the intersection of diagnostic and therapeutic radiopharmaceuticals, targeting high‑unmet medical needs across the globe. The company’s pipeline, combined with its Australian base and international reach, provides a platform for incremental revenue generation as clinical development milestones are achieved.
Analysts note that the company’s current valuation, driven by a modest market cap and a low price floor, offers a margin of entry for long‑term investors. With the 200‑day SMA acting as a bullish support and the 52‑week high a realistic target, the technical profile suggests a potential for further upside as the company advances its product candidates.
Forward‑Looking Perspective
While short‑term price swings may continue, the underlying fundamentals—particularly the company’s commitment to expanding its radiopharmaceutical portfolio—imply a trajectory of incremental growth. Investors monitoring the sector should consider Radiopharm Theranostics as a candidate for portfolio diversification, particularly given its current undervaluation relative to peers in the health‑care niche.
For deeper insights into Radiopharm Theranostics’ operations and pipeline, the company’s website at www.radiopharmtheranostics.com offers comprehensive details, alongside trading information available through ASX All Markets.